stating that “[u]ndue delay by 20 itself is insufficient to justify denying leave to amend, and the record here does not support any 21 additional ground – such as prejudice or bad faith – that would justify the denial of leave to amend 22 in combination with undue delay”
How later courts described this case
- stating that “[u]ndue delay by 20 itself is insufficient to justify denying leave to amend, and the record here does not support any 21 additional ground – such as prejudice or bad faith – that would justify the denial of leave to amend 22 in combination with undue delay”
Written by the judges who cited it.
The opinion
1
2
3
4 UNITED STATES DISTRICT COURT
5 NORTHERN DISTRICT OF CALIFORNIA
6
7 STALEY, et al., Case No. 19-cv-02573-EMC
8
ORDER GRANTING END-PAYOR
9 Plaintiffs, PLAINTIFFS’ MOTION TO AMEND
10 v. Docket No. 710
11 GILEAD SCIENCES, INC., et al.,
12 Defendants.
13
14
15 Currently pending before the Court is the end-payor plaintiffs (“EPPs”) motion for leave to
16 amend. The EPPs seek to add a new named plaintiff to the complaint, i.e., Blue Cross Blue Shield
17 Association (“BCBSA”). Having considered the parties’ briefs and accompanying submissions, as
18 well as the oral argument of counsel, the Court hereby GRANTS the motion.
19 I. DISCUSSION
20 A. Legal Standard
21 As an initial matter, the Court acknowledges that there is a dispute between the parties as
22 to which rule governs the pending motion to amend – Federal Rule of Civil Procedure 15, which
23 provides that a “court should freely give leave when justice so requires,” Fed. R. Civ. P. 15(a)(2),
24 or Rule 16, which provides that “[a] schedule may be modified only for good cause and with the
25 judge’s consent.” Fed. R. Civ. P. 16(b)(4); see also Fed. R. Civ. Pr. 16(b)(3) (providing that a
26 “scheduling order must limit the time to join other parties, amend the pleadings, complete
27 discovery, and file motions”).
1 December 2020, and May 2021, see Docket Nos. 342, 489, 611 (orders), do not specify a deadline
2 to join other parties or amend pleadings.
3 B. Futility
4 Defendants argue first that adding BCBS to the case should not be permitted because
5 amendment would be futile. Defendants advance two futility arguments: (1) under Lierboe v.
6 State Farm Mutual Automobile Insurance Co., 350 F.3d 1018 (9th Cir. 2003), a named plaintiff
7 who lacks standing to bring a claim cannot amend to add a new plaintiff to fix the standing
8 problem; and (2) even if Lierboe is not a bar, BCBS lacks Article III standing because it is not a
9 “true” payor but rather a middleman that “merely deposits premiums from the federal government
10 and federal employees into a fund from which it pays benefits.” Opp’n at 1 (emphasis omitted).
11 1. Lierboe
12 The Court rejects Defendants’ argument of futility based on Lierboe.
13 In Lierboe, the plaintiff brought a class action in which she was the only named plaintiff,
14 “seeking payments for insureds whose claims State Farm had limited by refusing to ‘stack’ more
15 than one [insurance] policy.” Id. at 1029. The Ninth Circuit stayed the appeal on the issue of
16 class certification while the Supreme Court of Montana “decided the threshold question of
17 whether [the plaintiff] had a stacking claim under her pertinent policies.” Id. at 1021. The
18 Montana Supreme Court held she did not. The Ninth Circuit noted that, “‘if none of the named
19 plaintiffs purporting to represent a class establishes the requisite of a case or controversy with the
20 defendants, none may seek relief on behalf of himself or any other member of the class.’” Id. at
21 1022. In other words, “if Lierboe [the plaintiff] has no stacking claim, she cannot represent others
22 who may have such a claim, and her bid to serve as a class representative must fail.” Id.
23 The Ninth Circuit then turned to the question of whether “the suit must be dismissed
24 without more, or if other proceeding may follow under which it may be possible that the suit can
25 proceed as a class action with another representative.” Id. at 1023. The court concluded in favor
26 of the former.
27 We are mindful of judicial economy considerations, especially
"stack" one coverage policy with another can properly proceed as a
1 "class" of plaintiffs in light of, among other considerations, any
case-by-case analysis required to compute each claimant's necessary
2 medical bills that are the subject of coverage. However, because
this is not a mootness case, in which substitution or intervention
3 might have been possible, we remand this case to the district court
with instructions to dismiss. We are persuaded by the Seventh
4 Circuit's approach in an analogous case, Foster v. Center Township
of LaPorte County, 798 F.2d 237, 244-45 (7th Cir. 1986), which
5 held that where the sole named plaintiff "never had standing" to
challenge a township's poor-relief eligibility guidelines, and where
6 "she never was a member of the class she was named to represent,"
the case must be remanded with instructions to dismiss.
7
8 Id.
9 In a footnote, the Ninth Circuit reiterated the mootness point: “If Lierboe initially had a
10 viable stacking claim that later became moot, then our law in an appropriate case would permit
11 substituting proper class representatives to allow the suit to proceed.” Id. at 1023 n.6. But here
12 the stacking claim was not rejected on mootness grounds; rather, “the Supreme Court of Montana
13 held that Lierboe had no stacking claim from the outset of her litigation.” Id.
14 According to Defendants, under Lierboe, there must be a named plaintiff who has standing
15 to assert each claim in a complaint; if there is a claim for which no named plaintiff has standing,
16 then the named plaintiff(s) is barred from moving to add a new plaintiff to assert that claim.
17 Although Defendants’ position is not entirely without logic, the Court does not agree with their
18 reading of Lierboe. Lierboe did not address the factual circumstance at issue in the instant case –
19 i.e., where the named plaintiffs do have standing to assert some claims and seek to represent
20 absent class members who have standing to assert analogous claims. Lierboe is thus not
21 dispositive. See Hensley-Maclean v. Safeway, Inc., No. 11-cv-01230-RS, 2015 U.S. Dist. LEXIS
22 84131, at *13 (N.D. Cal. June 29, 2015) (noting that “[i]t is questionable whether Rosen's
23 withdrawal from the suit should be labeled as having given rise to ‘mootness’” but, regardless,
24 “plaintiffs are correct that this is not a situation like Lierboe where standing, and therefore subject
25 matter jurisdiction, was absent from the outset[;] . . . there is no sound basis for denying leave to
26 amend at this juncture, given that the jurisdiction of the Court was properly invoked in the first
27 instance”); cf. Newberg on Class Actions § 2:8 (stating that, “if a case has only one class
1 and it must be dismissed; if the case only had this one class representative from the outset, then
2 there is no opportunity for a substitute class representative to take the named plaintiff's place
3 because this means that the court never had jurisdiction over the matter”); Sultanis v. Champion
4 Petfoods United States Inc., No. 21-cv-00162-EMC, 2021 U.S. Dist. LEXIS 145293, at *22 (N.D.
5 Cal. Aug. 3, 2021) (although not addressing Lierboe, holding that “whether a plaintiff can bring
6 claims on behalf of unnamed plaintiffs under the laws of states in which the named plaintiff does
7 not reside or was injured is a matter of typicality, adequacy, and predominance under Rule 23, not
8 Article III standing”).
9 2. Standing of BCBS
10 Defendants contend that, in any event, amendment would be futile because BCBSA lacks
11 Article III standing itself. According to Defendants, BCBSA
12 apparently lacks Article III standing because it is not an insurance
company; rather, BCBSA merely deposits premiums from the
13 federal government and federal employees into a fund from which it
pays benefits. “BCBSA does not have skin in the game; it does not
14 underwrite the risk in the insurance coverage. It merely acts as a
facilitator for [the Office of Personnel Management (“OPM”)].”
15 Helfrich v. Blue Cross & Blue Shield Ass’n, 804 F.3d 1090, 1100
(10th Cir. 2015); In re Blue Cross Blue Shield Antitrust Litig., 308
16 F. Supp. 3d 1241, 1250 (N.D. Ala. 2018) (same finding at summary
judgment).
17
18 Opp’n at 1-2; see also Opp’n at 12 (stating that “[m]ultiple courts have held that BCBSA does not
19 pay claims or bear any insurance risk for members who obtain federal employee health benefits; ;
20 rather, BCBSA is merely a middleman that facilitates payments by the federal government and
21 plan members to pharmacies and healthcare providers that offer products and services to those
22 members”).
23 Futility, however, is a high standard, and the Court is not satisfied that, at this juncture,
24 enough has been shown to establish that BCBSA definitively lacks standing. Plaintiffs dispute
25 Defendants’ characterization of BCBSA as a mere middleman. The proposed amendment to the
26 complaint alleges that BCBSA brings suit “in its capacity as the [insurance] carrier of the Service
27 Benefit Plan,” which is one of the Federal Employee Health Benefit Plans and that it “purchased
1 Atripla, Biktarvy, Complera, Descovy, Evotaz, Genvoya, Odefsey, Prezcobix, Stribild, Symtuza,
2 Truvada, and Viread other than for re-sale at supracompetitive prices during the Class Period.”
3 Prop. FAC, Addendum ¶¶ B1-B3. The allegations must be assumed as true for purposes of the
4 instant motion.
5 C. Untimeliness/Undue Delay
6 Defendants argue that, aside from futility, the motion to amend should be denied because
7 the EPPs did not timely move to amend and instead unduly delayed. Defendants emphasize that
8 they first challenged the EPPs’ ability to bring claims under the laws of 25 jurisdictions where
9 they did not make purchases back in September 2019, see Docket No. 143 (Mot. at 34-35), but the
10 EPPs chose not to try to cure that problem for some two years. Defendants suggest this also
11 constitutes bad faith on the part of the EPPs. In response, the EPPs argue that they acted with
12 diligence, and without bad faith, because they alerted the Court of their desire to amend within
13 weeks of the Ninth Circuit’s decision in Stromberg v. Qualcomm, Inc., 14 F.4th 1059 (9th Cir.
14 2021), which casts doubt on EPP’s ability to assert California claims on behalf of non-California
15 purchases (i.e., to assert that California claims may be applied nationwide).
16 Although Defendants’ argument on bad faith is not persuasive, their position on undue
17 delay has some merit. Nevertheless, undue delay by itself is not a reason to deny amendment; the
18 critical issue is whether the proposed amendment would prejudice Defendants. See United States
19 v. United Healthcare Ins. Co., 848 F.3d 1161, 1184 (9th Cir. 2016) (stating that “[u]ndue delay by
20 itself is insufficient to justify denying leave to amend, and the record here does not support any
21 additional ground – such as prejudice or bad faith – that would justify the denial of leave to amend
22 in combination with undue delay”).
23 D. Prejudice
24 Defendants contend that amendment should not be permitted because adding BCBSA to
25 the case would be unfairly prejudicial to them. In particular, Defendants assert that adding
26 BCBSA to the case and preparing the requisite defense within the current case management
27 deadlines is not possible. According to Defendants, the case schedule will need a seven-month
1 challenge BCBSA’s standing, and re-do their class certification analysis (e.g., on predominance
2 and typicality). The EPPs disagree, acknowledging that there may be some to adjust deadlines but
3 taking the position that the trial could still go forward in November 2022, as currently scheduled.
4 The Court is skeptical that trial could go forward in November 2022 if BCBSA were added
5 to the case. However, the Court finds that any prejudice to Defendants may be cured by extending
6 deadlines by a few months. An extension also makes sense given that (1) UHC has now brought
7 its own antitrust case based on the same underlying facts and that (2) even if the Court were to
8 deny amendment now, that would not preclude BCBSA from filing a new lawsuit which would
9 lead to the same case scheduling issues.
10 Accordingly, the Court hereby adopts the new case management schedule (see modified
11 dates).
12
13 Current Date Modified Date
14 Class certification motion [already filed] N/A
15 Rule 12 motion to dismiss N/A Filing of motion: 1/20/2022
16 hearing (related to BCBSA Hearing: 2/24/2022
17 only) [regularly noticed
18 hearing schedule]
19 Class certification 12/8/2021 6/2/2022
20 opposition and supporting
21 expert reports
22 Fact discovery cut-off 12/17/2021 12/17/2021 [non-BCBSA-
23 related discovery];
24 4/14/2022 [BCBSA-related
25 discovery]
26 Class certification reply and 1/12/2022 6/30/2022
27 supporting expert reports
1 Current Date Modified Date
2 Class certification hearing 2/3/2022 8/4/2022
3 Responsive expert reports 3/2/2022 7/22/2022
4 Rebuttal expert reports 3/24/2022 8/12/2022
5 Expert discovery cut-off 4/13/2022 9/2/2022
6 Last day to file dispositive 4/21/2022 9/8/2022
7 motions
8 Opposition to summary 5/26/2022 10/6/2022
9 judgment and related
10 Daubert motions [there may
11 be limits on the number of
12 Daubert motions and/or
13 page limits on the Daubert
14 motions]
15 Reply for summary 6/30/2022 10/27/2022
16 judgment and related
17 Daubert motions [see limits
18 above]
19 Summary judgment 7/28/2022 11/17/2022
20 hearing
21 Final pretrial conference 9/20/2022 1/26/2023
22 filings
23
Final pretrial conference 10/11/2022 2/28/2023
24
Trial 11/7/2022 3/27/2023
25
26 ///
27 ///
1 II. CONCLUSION
2 For the foregoing reasons, the Court grants the motion for leave to amend. The EPPs shall
3 immediately file the amended complaint. Defendants are not required at this time to file an
4 answer because the schedule above contemplates a Rule 12 motion related to BCBSA.
5 This order disposes of Docket No. 710.
6
7 IT IS SO ORDERED.
8
9 Dated: December 14, 2021
10
11 ______________________________________
EDWARD M. CHEN
12 United States District Judge
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27